HK Stock Market Move | GIANT BIOGENE (02367) rises over 7% again, controlling shareholder will continue to increase holdings from time to time. Institutions say that the impact of public opinion events on offline business is relatively small.

GIANT BIOGENE (02367) rose by over 7%, and at the time of writing, it was up by 4.88% to HKD 56.95, with a turnover of 742 million Hong Kong dollars. On the news front, on June 9th, GIANT BIOGENE announced that its controlling shareholder Juzi Holding plans to increase its stake in the company by a minimum of 200 million Hong Kong dollars within three to six months from the date of the announcement. On June 26th, the company announced that since the release of the plan to increase its holdings on June 9th, as of the date of the announcement, Juzi Holding has purchased a total of 1,056,600 shares of the company's stock in the market, with a total increase of approximately 53.5 million yuan. Juzi Holding may further increase its holdings of the company's shares in accordance with market conditions and applicable regulatory requirements. HAITONG INT'L released a research report stating that GIANT BIOGENE recently mentioned that the restructuring of the collagen protein industry is still in its early stages, with a lack of unified standards for testing and quality. The report pointed out that the company's online business was impacted to a certain extent during the 618 period, but overall it was manageable, and the current public relations event has had a relatively small impact on the company's offline business. The company maintains its annual performance guidance unchanged, and the approval of the three categories of medical devices has not been affected by the current public relations event. The company stated that its profit margin for the first half of 2025 has not been affected by the public relations event, and in the future, it will strengthen communication with consumers to enhance trust, with online marketing focusing on "people, goods, and venues."